Johnson & Johnson Trading Volume Drops 37% to $1.123 Billion Ranking 78th Amid Alzheimer's Research Breakthroughs

On July 24, 2025, Johnson & Johnson (JNJ) saw a trading volume of $1.123 billion, a 37.16% decrease from the previous day, ranking 78th in the day's stock market. The stock price rose by 0.27%, marking the fifth consecutive day of gains, with a total increase of 4.04% over the past five days.

Johnson & Johnson is set to present significant advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada, from July 27 to 31. The company will share insights from 12 abstracts, focusing on how tau impacts brain function in early Alzheimer's disease and the predictive strength of the plasma biomarker pTau217 for tracking cognitive decline in at-risk individuals. Additionally, findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a public-private partnership co-founded by Johnson & Johnson and Gates Ventures, will be introduced.

This research is expected to reinforce the company's position as a leader in Alzheimer's disease research and development. The presentation of these findings at a prestigious conference like AAIC is likely to attract significant attention from investors and the medical community, potentially boosting investor confidence in Johnson & Johnson's innovative capabilities and long-term growth prospects.